Comparison of platinum-based chemotherapy in patients older and younger than 70 years: An analysis of Southwest oncology group trials 9308 and 9509

Elizabeth M. Blanchard, James Moon, Paul J. Hesketh, Karen Kelly, Antoinette J. Wozniak, John Crowley, David R Gandara

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

PURPOSE: This retrospective analysis sought to investigate the safety, feasibility, and outcomes of platinum doublet therapy in patients aged 70 years or older with advanced non-small cell lung cancer compared with patients younger than 70 years who participated in two randomized phase III trials conducted by the Southwest Oncology Group. PATIENTS AND METHODS: Outcomes and toxicity data from fit patients with stage IIIB or stage IV non-small cell lung cancer treated with cisplatin/vinorelbine and carboplatin/paclitaxel were pooled from Southwest Oncology Group trials 9308 (S9308) and 9509 (S9509) and compared with respect to age. RESULTS: A total of 616 patients were available for efficacy analyses, of which 122 (20%) were aged 70 years or older. The median progression-free survival was 4 months in both age groups (p = 0.71), and response rates were similar. Overall survival was significantly higher in the younger patient cohort (median 9 months versus 7 months, p = 0.04). Individual parameters of toxicity were similar in both age groups. CONCLUSION: Although patients aged 70 years or older derived initial benefit from platinum-based therapy, survival was better in younger patients. Additional studies in this growing patient population are needed to develop treatment strategies that minimize toxicity and increase efficacy.

Original languageEnglish (US)
Pages (from-to)115-120
Number of pages6
JournalJournal of Thoracic Oncology
Volume6
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Platinum
Drug Therapy
Non-Small Cell Lung Carcinoma
Age Groups
Survival
Carboplatin
Paclitaxel
Cisplatin
Disease-Free Survival
Therapeutics
Safety
Population

Keywords

  • Elderly
  • NSCLC (non-small cell lung cancer)
  • Platinum-based therapy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Comparison of platinum-based chemotherapy in patients older and younger than 70 years : An analysis of Southwest oncology group trials 9308 and 9509. / Blanchard, Elizabeth M.; Moon, James; Hesketh, Paul J.; Kelly, Karen; Wozniak, Antoinette J.; Crowley, John; Gandara, David R.

In: Journal of Thoracic Oncology, Vol. 6, No. 1, 01.2011, p. 115-120.

Research output: Contribution to journalArticle

Blanchard, Elizabeth M. ; Moon, James ; Hesketh, Paul J. ; Kelly, Karen ; Wozniak, Antoinette J. ; Crowley, John ; Gandara, David R. / Comparison of platinum-based chemotherapy in patients older and younger than 70 years : An analysis of Southwest oncology group trials 9308 and 9509. In: Journal of Thoracic Oncology. 2011 ; Vol. 6, No. 1. pp. 115-120.
@article{5ec0a0ba42134d918c0ebbeb7b564aaa,
title = "Comparison of platinum-based chemotherapy in patients older and younger than 70 years: An analysis of Southwest oncology group trials 9308 and 9509",
abstract = "PURPOSE: This retrospective analysis sought to investigate the safety, feasibility, and outcomes of platinum doublet therapy in patients aged 70 years or older with advanced non-small cell lung cancer compared with patients younger than 70 years who participated in two randomized phase III trials conducted by the Southwest Oncology Group. PATIENTS AND METHODS: Outcomes and toxicity data from fit patients with stage IIIB or stage IV non-small cell lung cancer treated with cisplatin/vinorelbine and carboplatin/paclitaxel were pooled from Southwest Oncology Group trials 9308 (S9308) and 9509 (S9509) and compared with respect to age. RESULTS: A total of 616 patients were available for efficacy analyses, of which 122 (20{\%}) were aged 70 years or older. The median progression-free survival was 4 months in both age groups (p = 0.71), and response rates were similar. Overall survival was significantly higher in the younger patient cohort (median 9 months versus 7 months, p = 0.04). Individual parameters of toxicity were similar in both age groups. CONCLUSION: Although patients aged 70 years or older derived initial benefit from platinum-based therapy, survival was better in younger patients. Additional studies in this growing patient population are needed to develop treatment strategies that minimize toxicity and increase efficacy.",
keywords = "Elderly, NSCLC (non-small cell lung cancer), Platinum-based therapy",
author = "Blanchard, {Elizabeth M.} and James Moon and Hesketh, {Paul J.} and Karen Kelly and Wozniak, {Antoinette J.} and John Crowley and Gandara, {David R}",
year = "2011",
month = "1",
doi = "10.1097/JTO.0b013e3181fbebfd",
language = "English (US)",
volume = "6",
pages = "115--120",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "1",

}

TY - JOUR

T1 - Comparison of platinum-based chemotherapy in patients older and younger than 70 years

T2 - An analysis of Southwest oncology group trials 9308 and 9509

AU - Blanchard, Elizabeth M.

AU - Moon, James

AU - Hesketh, Paul J.

AU - Kelly, Karen

AU - Wozniak, Antoinette J.

AU - Crowley, John

AU - Gandara, David R

PY - 2011/1

Y1 - 2011/1

N2 - PURPOSE: This retrospective analysis sought to investigate the safety, feasibility, and outcomes of platinum doublet therapy in patients aged 70 years or older with advanced non-small cell lung cancer compared with patients younger than 70 years who participated in two randomized phase III trials conducted by the Southwest Oncology Group. PATIENTS AND METHODS: Outcomes and toxicity data from fit patients with stage IIIB or stage IV non-small cell lung cancer treated with cisplatin/vinorelbine and carboplatin/paclitaxel were pooled from Southwest Oncology Group trials 9308 (S9308) and 9509 (S9509) and compared with respect to age. RESULTS: A total of 616 patients were available for efficacy analyses, of which 122 (20%) were aged 70 years or older. The median progression-free survival was 4 months in both age groups (p = 0.71), and response rates were similar. Overall survival was significantly higher in the younger patient cohort (median 9 months versus 7 months, p = 0.04). Individual parameters of toxicity were similar in both age groups. CONCLUSION: Although patients aged 70 years or older derived initial benefit from platinum-based therapy, survival was better in younger patients. Additional studies in this growing patient population are needed to develop treatment strategies that minimize toxicity and increase efficacy.

AB - PURPOSE: This retrospective analysis sought to investigate the safety, feasibility, and outcomes of platinum doublet therapy in patients aged 70 years or older with advanced non-small cell lung cancer compared with patients younger than 70 years who participated in two randomized phase III trials conducted by the Southwest Oncology Group. PATIENTS AND METHODS: Outcomes and toxicity data from fit patients with stage IIIB or stage IV non-small cell lung cancer treated with cisplatin/vinorelbine and carboplatin/paclitaxel were pooled from Southwest Oncology Group trials 9308 (S9308) and 9509 (S9509) and compared with respect to age. RESULTS: A total of 616 patients were available for efficacy analyses, of which 122 (20%) were aged 70 years or older. The median progression-free survival was 4 months in both age groups (p = 0.71), and response rates were similar. Overall survival was significantly higher in the younger patient cohort (median 9 months versus 7 months, p = 0.04). Individual parameters of toxicity were similar in both age groups. CONCLUSION: Although patients aged 70 years or older derived initial benefit from platinum-based therapy, survival was better in younger patients. Additional studies in this growing patient population are needed to develop treatment strategies that minimize toxicity and increase efficacy.

KW - Elderly

KW - NSCLC (non-small cell lung cancer)

KW - Platinum-based therapy

UR - http://www.scopus.com/inward/record.url?scp=78651061149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651061149&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e3181fbebfd

DO - 10.1097/JTO.0b013e3181fbebfd

M3 - Article

C2 - 21107287

AN - SCOPUS:78651061149

VL - 6

SP - 115

EP - 120

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 1

ER -